SCHEMBL2865599

SCHEMBL2865599

O=C(NC(=S)Nc1ccc2c(c1)OC(c1ccccc1)O2)c1cccnc1C(=O)N1CCOCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 13/20 0.44
MAPT P10636 11/20 0.44
SMN1; SMN2 Q16637 8/20 0.43
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
NFKB1 P19838 2/20 0.43
NFKB2 Q00653 2/20 0.43
RELA Q04206 2/20 0.43
EPHX1 P07099 1/20 0.43
KMT2A Q03164 6/20 0.42
MEN1 O00255 5/20 0.42
ALOX12 P18054 4/20 0.42
LMNA P02545 3/20 0.42
TDP1 Q9NUW8 3/20 0.42
HTT P42858 1/20 0.42
GAA P10253 1/20 0.41
HPGD P15428 3/20 0.40
MAPK1 P28482 2/20 0.40
CYP3A4 P08684 2/20 0.39
CYP2C9 P11712 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2864605 0.85 ALDH1A1 (0.47) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL3135039 0.82 MAPT (0.47) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL14096269 0.81 ALDH1A1 (0.45) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL2867540 0.80 MAPT (0.45) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL2866057 0.76 ALDH1A1 (0.41) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL3151114 0.75 MAPT (0.50) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL2862559 0.74 LMNA (0.49) ALDH1A1MAPTRAB9AKMT2AMEN1
SCHEMBL2869492 0.73 ALDH1A1 (0.53) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL2868306 0.73 NPC1 (0.49) ALDH1A1MAPTSMN1; SMN2NPC1KMT2A
SCHEMBL4366783 0.72 ALDH1A1 (0.44) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023730-A1 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS (US) 2009-01-22 US claimed
EP-1747196-A2 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION Achillion Pharmaceuticals, Inc. (US) 2007-01-31 EP claimed
WO-2006083271-A2 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. (US) 2006-08-10 WO claimed
US-20060025416-A1 Substituted aryl acylthioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2006-02-02 US claimed
US-7767706-B2 Substituted aryl acylthioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2010-08-03 US disclosed
US-20090023730-A1 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS (US) 2009-01-22 US disclosed
US-20060025416-A1 Substituted aryl acylthioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025416-A1 Substituted aryl acylthioureas and related compounds; inhibitors of viral replication PIGS, NAT1, AADAC ALDH1A1 176/4885MAPT 3157/4885SMN1; SMN2 3029/4885
US-20090023730-A1 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION PIGS, NAT1, AADAC ALDH1A1 176/4885MAPT 3157/4885SMN1; SMN2 3029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.